Spots Global Cancer Trial Database for Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Official Title: Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Study ID: NCT02304809

Conditions

Solid Tumors

Hematologic Cancers

Metastatic Cancers

Interventions

Vemurafenib

Study Description

Brief Summary: Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment. To explore the efficacy of vemurafenib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the vemurafenib target gene, per cohort.

Detailed Description: This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent vemurafenib as a monotherapy in cohorts of patients with identified activating molecular alterations in BRAF gene. A cohort is defined by a pathology and a BRAF- alteration (eg ovarian cancer with BRAF V600 mutation). To explore the efficacy of vemurafenib per pathology and per target. To assess the safety profile of vemurafenib. To explore whether molecularly driven, high quality multi-tumor screening phase II trials are feasible in the French multiinstitutional, multidisciplinary setting. To investigate the additional molecular mechanisms in patients with tumor response versus patients without tumor response within the same cohort. The study will include 11 cohorts of adult patients with the following cancers and alterations: * NSCLC V600 mutated * Ovarian cancer V600 mutated * Cholangiocarcinoma V600 mutated * Thyroid cancer V600 mutated * Prostatic cancer V600 mutated * Bladder cancer V600 mutated * Sarcoma/GIST V600 mutated * Multiple myeloma V600 mutated * Chronic Lymphocytic Leukemia (CLL) V600 mutated * Hairy cell leukaemia (HCL) V600 mutated (this excludes Hairy Cell Leukemia variant types, marginal zone splenic lymphoma (MZL), splenic red pulp lymphoma (SRPL) patients) * Other pathology / other alteration than those pre-defined above. The cohort named "Other" will include adult patients with tumor harboring BRAF genomic alterations only tested via emerging biomarkers programs or molecular pangenomic programs: * with any other non-predefined pathology harboring a V600 mutation * Same or other non-predefined pathology harboring non V600 activating mutations * Same or other non-predefined pathology harboring BRAF amplifications.